NCT01596166View on ClinicalTrials.gov

Intravenous Ketorolac and Metoclopramide for Pediatric Migraine in the Emergency Department

PHASE4CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Probable MigraineMigraine With AuraMigraine Without Aura
Interventions
DRUG

Ketorolac Tromethamine

Ketorolac 0.5 mg/kg (max 30 mg) IV

DRUG

Metoclopramide

Metoclopramide 0.2 mg/kg (max 10 mg) IV

Trial Locations (2)

T3B 6A8

Alberta Children's Hospital, Calgary

T6G 2C8

Stollery Children's Hospital, Edmonton

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

University of Alberta

OTHER

NCT01596166 - Intravenous Ketorolac and Metoclopramide for Pediatric Migraine in the Emergency Department | Biotech Hunter | Biotech Hunter